Cardioprotective effect of mangiferin on left ventricular remodeling in rats
Abstract
The purpose of this study was to clarify the protective role of mangiferin on postinfarction myocardial remodeling and potential mechanisms. The myocardial infarction (MI) model was established by ligating the left anterior descending coronary artery. Cardiac function, myocardial apoptosis and fibrosis, serum tumor necrosis factor-α (TNF-α) and phosphorylated p38 mitogen-activated protein kinase (MAPK) were examined by echocardiography, histological staining, ELISA and Western blot, respectively. Mangiferin attenuated MI and prevented the development of intercellular fibrosis. Western blotting underscores that the p38 MAPK cascade plays an important role in the cardioprotective effect of mangiferin during MI. Inhibition of p38 MAPK significantly decreased serum TNF-α levels. Transferase-mediated uridine nick end labeling and Masson staining also showed that mangiferin reduced apoptosis and fibrosis in myocardium remodeling. Based on these results, we conclude that mangiferin has a therapeutic effect on post-MI left ventricular remodeling and improves cardiac function.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mangiferin has a therapeutic effect on post-MI left ventricular remodeling and improves cardiac function.
“In addition, mangiferin has a therapeutic effect on post-MI left ventricular remodeling and improves cardiac function.”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [80]
Mangiferin administration (20 mg/kg for 4 weeks) restores cardiac ejection function, reduces accumulation of TNF-alpha and cleaved caspase-3, and upregulates Bcl-2.
“Mangiferin administration (20 mg/kg for 4 weeks) restores the function of cardiac ejection, reduces the accumulation of TNF-α and cleaved caspase-3, and upregulates Bcl-2 (80).”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [80]
Mangiferin improved heart blood flow parameters and fiber disturbance in a dose-dependent manner following a single intravenous injection (5, 10 or 20 mg/kg) in a MI experimental model.
“It has also been demonstrated that mangiferin improved heart blood flow parameters and fiber disturbance in a dose-dependent manner, following a single intravenous injection of mangiferin (5, 10 or 20 mg/kg) in a MI experimental model (80).”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [80]
Cited by
Sorted by citations
Mangiferin: An effective therapeutic agent against several disorders (Review)
Du, S., Liu, H., Lei, T., Xie, X., Wang, H., He, X., Tong, R., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9529 · Cited by 139 · see citing works
“Pan et al (60) demonstrated that through regulation of Bcl-2, apoptosis regulator (Bcl-2) and Bcl-2 associated X, apoptosis regulator (Bax) expression, mangiferin potently inhibits tumor cell proliferation and induces apoptosis in nasopharyngeal carcinoma cells.”
InfluentialMorozkina, S. N., Nhung Vu, T. H., Generalova, Y. E., Snetkov, P. P., & Uspenskaya, M. V. (2021) · Biomolecules · doi:10.3390/biom11010079 · Cited by 82 · see citing works
- Authors
- Zheng, D., Hou, J., Xiao, Y., Zhao, Z., & Chen, L.
- Affiliations
- Army Medical University (CN)
- Chengdu Military General Hospital (CN)
- PLA Navy General Hospital (CN)
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2012
- Volume
- 90
- Issue
- 1-2
- Pages
- 78-87
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W1992580579
- Cited by
- 23
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 4 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 4
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
- Keywords
- mangiferin, left ventricular remodeling, myocardial infarction, cardioprotection, p38 MAPK, TNF-α, cardiomyocyte apoptosis, myocardial fibrosis, cardiac function, flavonoids
- MeSH terms
- Animals, Blood Pressure, Cardiotonic Agents, Drugs, Chinese Herbal, Fibrosis, Male, Myocardial Infarction, Myocardium, Tumor Necrosis Factor-alpha, Rats, Sprague-Dawley, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Ventricular Remodeling, Xanthones, p38 Mitogen-Activated Protein Kinases, Rats, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
